Cardiovascular disease: risk assessment and reduction, including lipid modification
KEYWORDS: people, cvd, risk, treatment, statin, statins, committee, recommendations, prevention, evidence, cholesterol, recommendation, lipid-lowering, primary, amended

familial hypercholesterolaemia) or other inherited disorders of lipid metabolism. [May 2023] 1.1.10 Recognise that CVD risk tools may underestimate risk in certain groups of people, including but not limited to: • people treated for HIV • people already taking medicines to treat CVD risk factors • people who have recently stopped smoking • people taking medicines that can cause dyslipidaemia, such as immunosuppressant drugs • people with severe mental illness • people with autoimmune disorders, and other systemic inflammatory disorders. [May 2023] 1.1.11 Consider people aged 85 or older to be at increased risk of CVD because of age alone, particularly people who smoke or have raised blood pressure. [May 2023] For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on full formal risk assessment. Full details of the evidence and the committee's discussion are in evidence review A: CVD risk assessment tools: primary prevention. Communication about risk assessment, lifestyle changes and treatment 1.1.12 Follow the recommendations on communication in NICE's guidelines on patient experience in adult NHS services and shared decision making. [2014] 1.1.13 Set aside adequate time during the consultation to provide information on
